Literature DB >> 15466961

Magnesium gluconate offers no more protection than magnesium sulphate following diffuse traumatic brain injury in rats.

Renee J Turner1, K W Dasilva, C O'Connor, Corinna van den Heuvel, Robert Vink.   

Abstract

OBJECTIVE: Previous studies have demonstrated that magnesium salts, including the sulphate and chloride forms, are neuroprotective following traumatic brain injury (TBI). Recently, studies in cardiac ischaemia/reperfusion injury have demonstrated that the gluconate salt of magnesium may provide superior protection against oxidative damage and postischaemic dysfunction than MgSO(4). We have therefore compared the efficacy of both MgSO(4) and magnesium gluconate (MgGl(2)) on outcome following diffuse TBI in rats.
METHODS: Adult male Sprague-Dawley rats were injured using the 2-metre impact acceleration model of diffuse TBI. At 30 min after injury, animals were administered with either 250 micromoles/kg i.v. MgSO(4), MgGl(2), or equal volume saline vehicle. Thereafter, animals were assessed for motor and cognitive outcome using the rotarod and Barnes maze, respectively, or their brains removed at 3 days after TBI and used for histological examination.
RESULTS: Treatment with either magnesium salt significantly improved functional outcome as compared to vehicle treated controls. Similarly, treatment with either magnesium salt attenuated the degree of histological dark cell change at 3 days after TBI relative to the vehicle treated animals. There were no significant differences between the magnesium treated groups.
CONCLUSIONS: We conclude that MgSO(4) and MgGl(2) are equally neuroprotective following TBI. Our results suggest that MgGl(2) may only be more effective in conditions that produce ischaemia, where high concentrations of reactive oxygen species are generated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15466961     DOI: 10.1080/07315724.2004.10719399

Source DB:  PubMed          Journal:  J Am Coll Nutr        ISSN: 0731-5724            Impact factor:   3.169


  6 in total

Review 1.  Animal modelling of traumatic brain injury in preclinical drug development: where do we go from here?

Authors:  Niklas Marklund; Lars Hillered
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

2.  Experimental diffuse brain injury results in regional alteration of gross vascular morphology independent of neuropathology.

Authors:  Jenna M Ziebell; Rachel K Rowe; Jordan L Harrison; Katharine C Eakin; Taylor Colburn; F Anthony Willyerd; Jonathan Lifshitz
Journal:  Brain Inj       Date:  2015-12-08       Impact factor: 2.311

3.  In-depth investigation on physicochemical and thermal properties of magnesium (II) gluconate using spectroscopic and thermoanalytical techniques.

Authors:  Mahendra Kumar Trivedi; Neena Dixit; Parthasarathi Panda; Kalyan Kumar Sethi; Snehasis Jana
Journal:  J Pharm Anal       Date:  2017-03-22

Review 4.  Preclinical Models of Traumatic Brain Injury: Emerging Role of Glutamate in the Pathophysiology of Depression.

Authors:  Darik A O'Neil; Melissa A Nicholas; Naima Lajud; Anthony E Kline; Corina O Bondi
Journal:  Front Pharmacol       Date:  2018-06-01       Impact factor: 5.810

Review 5.  Neuro-Inflammation Modulation and Post-Traumatic Brain Injury Lesions: From Bench to Bed-Side.

Authors:  Alice Jacquens; Edward J Needham; Elisa R Zanier; Vincent Degos; Pierre Gressens; David Menon
Journal:  Int J Mol Sci       Date:  2022-09-23       Impact factor: 6.208

Review 6.  Current Methods of Magnetic Resonance for Noninvasive Assessment of Molecular Aspects of Pathoetiology in Multiple Sclerosis.

Authors:  Petra Hnilicová; Oliver Štrbák; Martin Kolisek; Egon Kurča; Kamil Zeleňák; Štefan Sivák; Ema Kantorová
Journal:  Int J Mol Sci       Date:  2020-08-25       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.